NIH RFA-DK-26-310: Diabetes Research Centers (P30 Clinical Trial Optional)

Captured cycle: This page is retained for historical guidance. Confirm whether the program has reopened before planning an application.

NIH RFA-DK-26-310: Diabetes Research Centers (P30 Clinical Trial Optional)

For teams building a durable diabetes research ecosystem rather than a single project, RFA-DK-26-310 is one of the most structurally important federal opportunities in the diabetes space. It is a P30 center grant pathway that funds an organized, institution-hosted network of investigators and shared cores under a coordinated administration and budget model. The NOFO is positioned as a long-duration, high-coordination opportunity: if your institution has multiple active diabetes investigators who can benefit from shared technical and translational infrastructure, this mechanism is designed to scale that collaboration across a formal center.

The announcement is a reissue of an earlier NIDDK framework and is active with deadlines in both 2026 and 2027 cycles. The 2026 cycle included a March 10, 2026 due date; the 2027 cycle includes a January 27, 2027 due date. The NOFO expires January 28, 2027. This is a relevant one for 2027 planning because it clearly lists a 2027 submission window and an anticipated 2027 start profile.

Key details

What this opportunity is designed to fund

This NOFO is not a project grant for one laboratory. It is explicitly a center mechanism. The NIH describes Diabetes Research Centers as a structure that brings basic and clinical investigators together around shared resources and coordinated leadership. The explicit model includes:

• an Administrative Core (with an enrichment component),
• at least two and up to five Biomedical Research Cores, and
• a Pilot and Feasibility (P&F) program.

The grant is intended to improve capability by reducing redundancy, creating critical shared services, and strengthening the strategic cohesion of a local/nationally relevant diabetes research base. The NOFO puts emphasis on:

• integrated preclinical and clinical research,
• stronger collaboration across investigators,
• improved communication and mentorship environment,
• synergy with other NIDDK-supported programs,
• shared technical resources that individual investigators may not obtain efficiently alone.

This is especially relevant for institutions with a real concentration of diabetes and metabolic disease science and strong evidence of prior NIH/peer-reviewed output. A center cannot be a loose collection of unrelated projects; it must be built around explicit research themes and strong thematic coherence.

Unlike some one-off NIH grant announcements, the NOFO makes center structure a core deliverable. Review logic is therefore structural and collective, not just topical. The center application asks whether your infrastructure proposal creates more value together than project-by-project funding could deliver.

Who this opportunity fits

Best fit

The strongest matches are typically:

• University medical centers with multiple active diabetes investigators already funded from federal sources.
• Institutes with established diabetes groups spanning at least two or more disciplinary areas (for example, endocrinology, inflammation, neuroscience, omics, engineering, data science).
• Teams that already maintain or can justify a shared core ecosystem with high utilization.
• Leadership teams that can show a clear and operational succession plan.

Applicants should be able to present a clear research base with:

1. existing peer-reviewed funding strength,
2. a documented publication/impact record,
3. evidence of interdisciplinary and translational momentum,
4. a realistic path for measurable Center growth or focus improvement.

Who should avoid this NOFO

If you have one isolated lab, two independent pilot projects, or no realistic need for shared infrastructure, this is a poor fit. A small, narrowly scoped team often benefits more from R01/R21-type opportunities because a P30 requires significant organizational and governance commitment.

Eligible institution types and constraints

The eligibility framework is broad on institutional class but geographically constrained:

• Higher education institutions, nonprofits, for-profit organizations (including small business), and public entities are included,
• non-domestic participants and non-U.S. components are not eligible,
• foreign entities may not participate as eligible applying organizations under this NOFO.

Because this is not a fellowship, this NOFO assumes organized institutional capacity around grants operations, administrative tracking, and compliance readiness. If your group has unstable administrative support, that weakness will be exposed during review and in pre-award checks.

Timeline and application flow (2026/2027 cycle)

For applicants planning against a 2026 or 2027 window, the NOFO gives explicit submission points:

• Open: 2026-02-10,
• New application due: 2026-03-10,
• Additional due cycle: 2027-01-27,
• Expiration: 2027-01-28.

All applications are due by 5:00 PM local applicant time. NIH/Grants.gov applies strict late rules. A common operational trap is assuming one missed day is harmless because of weekend timing. The NOFO states that late submissions are not accepted.

Submission route is strictly electronic:

1. Prepare in NIH ASSIST, or
2. Prepare through an institutional system-to-system method and submit to Grants.gov while tracking status in eRA Commons.

Changed/corrected applications must still be submitted by the due timestamp, and reviewers are strict on this. This is especially important for large P30 packages where final file assembly often introduces last-minute form errors.

From a planning perspective, the safer strategy is to treat this as a two-phase timeline:

• T-minus 4 to 5 weeks: finalize center architecture and membership logic,
• T-minus 3 weeks: complete draft application attachments, especially grant support, membership tables, core plans,
• T-minus 2 weeks: run compliance checklist across required registrations and signatures,
• T-minus 7–10 days: pre-submit internal check against reviewer criteria and technical attachments.

This sequencing matters because the NOFO expects substantial center planning beyond narrative writing.

Core application design: what to deliver well

Structural requirements

The center design must define three major components:

• Administrative core with coordination mechanisms, governance, and enrichment responsibilities,
• Biomedical research cores (minimum two, maximum five),
• Pilot and Feasibility program with a transparent solicit-review-support process.

You should make these components easy to review. For each core:

• identify who uses it,
• show why it is unique and not merely duplicate,
• justify expected utilization,
• provide quality and governance plans.

The NOFO explicitly expects cores to support meaningful interdisciplinary work in diabetes, endocrine, or metabolic research, and values services that are difficult or inefficient to build individually.

What belongs in the application package

The NOFO prescribes specific attachment types and tables:

• Grant Support table (current and pending grant support by Center investigator),
• Description of Center Research Base (short investigator narratives),
• Core Use table (users and usage plans),
• Facilities and resources summary and core service details,
• Research Strategy that ties Center structure to mission and outcomes,
• P&F plan describing project solicitation, review, mentoring and monitoring,
• Project period plan up to five years.

This is not a generic narrative exercise; the quality of organization and traceability is review-critical.

Eligibility details that affect package quality

The NOFO does not require cost sharing, which helps lower administrative barriers, but does require that your institutional registrations are in place and current. Incomplete registrations can invalidate submission readiness.

It also emphasizes non-duplication. Applications that are highly overlapping with active applications may be rejected, including some new/renewal/resubmission combinations. Build internal gating to check overlap before final submission.

Review logic and what reviewers reward

Reviewers do not only score scientific novelty. For this NOFO, they evaluate:

1. Significance of the Center for the diabetes field,
2. Investigative capability, including director and core leadership,
3. Innovation in methods, technologies, and cross-unit integration,
4. Approach around organization, user flow, quality control, and P&F structure,
5. Environment and cross-institution support,
6. Additional criteria around timelines, human subjects, resources, and core usage where relevant.

The NOFO also supports top-half discussability logic at review stage; in practice this means a clear, compelling center story is mandatory even if scientific merit is strong.

The final funding step includes a second-level review by the NIDDK Advisory Council. This means proposals must be strong enough to survive both domain review and program-priority alignment. Reviewers are also sensitive to alignment with program priorities, reviewer-scored feasibility, and practical budget rationality.

Common mistakes that reduce competitiveness

1. Submitting a center that looks like a collection of unrelated grants
   • Reviewers expect a coherent theme and clear integration.
2. Weak research-base evidence
   • Simply stating a strong institutional profile is not enough; include concrete current funding, publications, and thematic concentration.
3. Underdeveloped core utilization plan
   • If a core is proposed, include realistic user demand, prioritization method, and quality control.
4. Inadequate attachment quality
   • Missing Grant Support tables and research-base narratives are common technical failures.
5. Unclear membership rules or succession planning
   • A Center needs durable governance and replacement continuity.
6. Ignoring no-overlap policy
   • Multi-application behavior is allowed only when scientifically distinct and compliant with non-overlap language.
7. Delayed registrations
   • eRA Commons, SAM, and required identifiers must be ready before submission.
8. Unclear clinical-trial handling
   • Even though clinical trials are optional, if present, clinical trial governance and monitoring should be explicit.

Practical strategy for a strong application

Use a center-first blueprint:

• Map each investigator to a thematic sub-thread and core support need.
• Write one-page evidence blocks per core with utilization logic.
• Convert every requested attachment into a reviewer evidence item:
  • Grant support shows seriousness of base,
  • Membership list shows depth,
  • Core use matrix shows feasibility.
• Include a one-page “how this center changes outcomes” diagram or narrative even if no diagram is required.
• Align your narrative with program intent: mentorship, translational collaboration, national relevance.

Build explicit operational readiness:

• who leads each core and who monitors usage,
• how conflicts and prioritization are resolved,
• how P&F projects are selected and monitored,
• how enrichment activities support traineeship and community building.

When done well, a P30 application is not simply stronger than a sum of projects; it is an argument that the institution can produce better diabetes science through coordinated infrastructure.

FAQ

Is clinical research required?

No. The announcement is Clinical Trial Optional and open to non-trial-centered Center strategies.

Can one institution submit multiple applications?

The text includes both legacy-style summary language and sectioned eligibility language on applications and overlap. The practical takeaway is to avoid duplicate or overlapping proposals and only submit multiple applications if they are scientifically distinct. Verify intent with your Program Official before submitting more than one.

What is the budget structure?

The NOFO does not present one fixed total award amount in the open lines shown; budgets are determined by proposal scope and reviewed against Center structure and utilization. A five-year period is the maximum support horizon.

Are non-U.S. collaborators allowed?

Foreign components are restricted and non-domestic entities are not eligible as applying organizations. Collaborations must be managed within the eligibility framework.

What happens after submission?

Applications receive written peer review, then an advisory council-level decision pathway. If moved toward funding, NIH may request additional just-in-time information before award.

Official links and next actions

Primary source:

• NOFO text: https://files.simpler.grants.gov/opportunities/4ed18a56-4304-49a2-b9b4-87b4d78eb4f1/attachments/606e2919-e0bc-4eab-bef0-7ea1a513239b/RFA-DK-26-310-Full-Announcement.html

Helpful contact points in the NOFO:

• eRA Service Desk (submission platform issues),
• Grants.gov Support Center (Grants.gov registration and workspace/submission),
• NIDDK Division of Diabetes, Endocrinology and Metabolic Diseases (scientific/research contact),
• NIDDK Grants Management Branch (awards administration support).

For a first practical pass, use the NOFO’s table fields and checklist as your build framework, then cross-check every required attachment name before final submission. The Center model is unforgiving of omissions: this is not a short-form submission, and review quality depends heavily on program architecture quality, not only scientific prestige.